Lucid Diagnostics Releases Data Demonstrating Clinical Utility Of EsoGuard Esophageal Precancer Detection In Fire Fighters
Portfolio Pulse from Happy Mohamed
Lucid Diagnostics Inc. (NASDAQ:LUCD), a subsidiary of PAVmed Inc. (NASDAQ:PAVM), has released positive data from a retrospective analysis demonstrating the clinical utility of EsoGuard® Esophageal DNA testing for the detection of esophageal precancer in fire fighters. The study shows 100% concordance between EsoGuard test results and subsequent medical decision-making. The release of these data supports recently proposed federal legislation seeking to fund guaranteed firefighter access to early detection tests such as EsoGuard.
September 06, 2023 | 1:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lucid Diagnostics' positive data on EsoGuard Esophageal DNA testing could potentially increase its market value and attract more investors.
The positive data on EsoGuard Esophageal DNA testing demonstrates its effectiveness in detecting esophageal precancer, which could increase its demand and subsequently boost Lucid Diagnostics' market value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
As a majority owner of Lucid Diagnostics, PAVmed Inc. could potentially benefit from the positive data on EsoGuard Esophageal DNA testing.
As a majority owner of Lucid Diagnostics, PAVmed Inc. could see a positive impact on its stock price due to the positive data on EsoGuard Esophageal DNA testing.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80